Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase
- 11 July 2007
- journal article
- basic science
- Published by Wolters Kluwer Health in AIDS
- Vol. 21 (11) , 1405-1414
- https://doi.org/10.1097/qad.0b013e3281ac229b
Abstract
Objectives: The K65R mutation in HIV-1 reverse transcriptase (RT) decreases susceptibility to all approved nucleoside reverse transcriptase inhibitors (NRTI) except zidovudine by selectively decreasing the incorporation of the NRTI triphosphate compared with the natural deoxyribonucleotide triphosphate substrate. Thymidine analog mutations (TAMs) confer high-level resistance to zidovudine and cross-resistance to other NRTI by increasing excision of the chain-terminating NRTI monophosphate via a phosphorolytic cleavage reaction. Recent virology and genetic studies have shown bidirectional antagonism between K65R and TAMs. The aim of this study was to elucidate the biochemical and structural mechanisms responsible for this antagonism. Methods: Steady-state and pre-steady-state kinetic analyses of NRTI triphosphate incorporation and NRTI monophosphate excision by RT containing K65R or TAMs were conducted and complemented by molecular modeling. Results: The addition of K65R to two clinically relevant combinations of TAMs (M41L/L210W/T215Y or D67N/K70R/T215F/K219Q) significantly reduced the recombinant enzymes' ability to excise all chain-terminating NRTI monophosphate. Transient kinetic analyses showed that TAMs decreased the extent to which RT containing K65R could discriminate against D-nucleotide analogs, but not L-nucleotide analogs, by partly restoring the maximum rate of NRTI triphosphate incorporation. In addition, the TAMs combination D67N/K70R/T215F/K219Q decreased susceptibility to the L-nucleotide lamivudine by a discrimination mechanism, whereas the M41L/L210W/T215Y combination had little effect on susceptibility to lamivudine. Conclusion: K65R antagonizes the NRTI monophosphate excision activity of RT containing TAMs. TAMs antagonize the ability of K65R RT to discriminate against the nucleotide analog. Therapies including NRTI that select for both TAMs and K65R may prolong treatment response through the mutually antagonistic interactions between these resistance mutations.Keywords
This publication has 42 references indexed in Scilit:
- Structural Determinants and Molecular Mechanisms for the Resistance of HIV-1 RT to Nucleoside AnaloguesCurrent Drug Metabolism, 2004
- Mechanistic Basis for Reduced Viral and Enzymatic Fitness of HIV-1 Reverse Transcriptase Containing Both K65R and M184V MutationsJournal of Biological Chemistry, 2004
- The Molecular Mechanism of Multidrug Resistance by the Q151M Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Its Suppression Using α-Boranophosphate Nucleotide AnaloguesJournal of Biological Chemistry, 2002
- Mechanism-based Suppression of Dideoxynucleotide Resistance by K65R Human Immunodeficiency Virus Reverse Transcriptase Using an α-Boranophosphate Nucleoside AnalogueJournal of Biological Chemistry, 2001
- Selective Excision of AZTMP by Drug-Resistant Human Immunodeficiency Virus Reverse TranscriptaseJournal of Virology, 2001
- Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs)Cellular and Molecular Life Sciences, 2000
- Inhibitors of HIV- I reverse transcriptasePublished by Elsevier ,2000
- A Mechanism of AZT ResistanceMolecular Cell, 1999
- Mechanistic Studies Examining the Efficiency and Fidelity of DNA Synthesis by the 3TC-Resistant Mutant (184V) of HIV-1 Reverse TranscriptaseBiochemistry, 1999
- Phenotypic Mechanism of HIV-1 Resistance to 3‘-Azido-3‘-deoxythymidine (AZT): Increased Polymerization Processivity and Enhanced Sensitivity to Pyrophosphate of the Mutant Viral Reverse TranscriptaseBiochemistry, 1998